Hyderabad, Sep 9 : Dr Reddy’s Laboratories Limited along with its subsidiaries together on Wednesday announced the launch of Remdesivir, under a brand name Redyx in India for the COVID-19 treatment.
The launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddy’s the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India, a company statement here said.
Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms.
Mr M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories, said “We will continue our efforts to develop products that address significant unmet needs of patients.
The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from Covid-19 in India.”